Article Correctness Is Author's Responsibility: $11.4 million NIH grant advances drug to treat nicotine addiction

(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys, Camino Pharma, LLC and University of California San Diego School of Medicine have been awarded an $11.4 million grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) to advance a novel drug candidate for nicotine addiction into first-in-human Phase 1 studies. The drug targets a neuronal signaling pathway underlying addictive behaviors, and would be a first-in-class medication to help people quit smoking.